Fmr LLC Purchases 39,204 Shares of Coherus BioSciences, Inc. (NASDAQ:CHRS)

Fmr LLC increased its position in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS) by 21.1% during the 3rd quarter, Holdings Channel reports. The firm owned 225,113 shares of the biotechnology company’s stock after acquiring an additional 39,204 shares during the period. Fmr LLC’s holdings in Coherus BioSciences were worth $234,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Los Angeles Capital Management LLC boosted its stake in Coherus BioSciences by 344.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 930,132 shares of the biotechnology company’s stock worth $967,000 after purchasing an additional 720,672 shares during the period. AQR Capital Management LLC bought a new position in shares of Coherus BioSciences during the second quarter worth $1,246,000. Marshall Wace LLP grew its stake in Coherus BioSciences by 177.3% during the second quarter. Marshall Wace LLP now owns 420,326 shares of the biotechnology company’s stock valued at $727,000 after acquiring an additional 268,763 shares in the last quarter. Renaissance Technologies LLC increased its holdings in Coherus BioSciences by 159.2% in the 2nd quarter. Renaissance Technologies LLC now owns 394,828 shares of the biotechnology company’s stock valued at $683,000 after acquiring an additional 242,500 shares during the last quarter. Finally, XTX Topco Ltd lifted its stake in Coherus BioSciences by 304.9% in the 2nd quarter. XTX Topco Ltd now owns 271,433 shares of the biotechnology company’s stock worth $470,000 after purchasing an additional 204,391 shares in the last quarter. Hedge funds and other institutional investors own 72.82% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on CHRS. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 target price on shares of Coherus BioSciences in a report on Wednesday, December 4th. Robert W. Baird upped their price objective on Coherus BioSciences from $4.00 to $6.00 and gave the stock an “outperform” rating in a report on Thursday, December 5th. Finally, StockNews.com lowered shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a report on Saturday, October 19th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $5.38.

Coherus BioSciences Price Performance

NASDAQ:CHRS opened at $1.52 on Friday. The firm has a market capitalization of $175.12 million, a price-to-earnings ratio of -19.00 and a beta of 0.86. The business has a 50 day simple moving average of $1.10 and a 200-day simple moving average of $1.30. Coherus BioSciences, Inc. has a 1 year low of $0.66 and a 1 year high of $3.70.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.